Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Biomark ; 27(2): 225-242, 2020.
Article in English | MEDLINE | ID: mdl-32083575

ABSTRACT

BACKGROUND: Deregulated microRNAs (miRNAs) in breast and gynecological cancer might contribute to improve early detection of female malignancies. OBJECTIVE: Specification of miRNA types in serum and urine as minimally-invasive biomarkers for breast (BC), endometrial (EC) and ovarian cancer (OC). METHODS: In a discovery phase, serum and urine samples from 17 BC, five EC and five OC patients vs. ten healthy controls (CTRL) were analyzed with Agilent human miRNA microarray chip. Selected miRNA types were further investigated by RT-qPCR in serum (31 BC, 13 EC, 15 OC patients, 32 CTRL) and urine (25 BC, 10 EC, 10 OC patients, 30 CTRL) applying two-sample t-tests. RESULTS: Several miRNA biomarker candidates exhibited diagnostic features due to distinctive expression levels (serum: 26; urine: 22). Among these, miR-518b, -4719 and -6757-3p were found specifically deregulated in BC serum. Four, non-entity-specific, novel biomarker candidates with unknown functional roles were identified in urine (miR-3973; -4426; -5089-5p and -6841). RT-qPCR identified miR-484/-23a (all p⩽ 0.001) in serum as potential diagnostic markers for EC and OC while miR-23a may also serve as an endogenous control in BC diagnosis. CONCLUSIONS: Promising miRNAs as liquid biopsy-based tools in the detection of BC, EC and OC qualified for external validation in larger cohorts.


Subject(s)
Biomarkers, Tumor/genetics , Breast Neoplasms/genetics , Endometrial Neoplasms/genetics , Ovarian Neoplasms/genetics , Aged , Biomarkers, Tumor/blood , Biomarkers, Tumor/urine , Breast Neoplasms/blood , Breast Neoplasms/pathology , Breast Neoplasms/urine , Case-Control Studies , Endometrial Neoplasms/blood , Endometrial Neoplasms/pathology , Endometrial Neoplasms/urine , Female , Humans , Liquid Biopsy/methods , Middle Aged , Ovarian Neoplasms/blood , Ovarian Neoplasms/pathology , Ovarian Neoplasms/urine , Prognosis
2.
Gynecol Endocrinol ; 31(7): 578-81, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26036805

ABSTRACT

Critical steps of embryo implantation are controlled by progesterone. These processes can be interrupted by progesterone receptor (PR) antagonists, e.g. drugs used for abortion. Antiprogestin effects induced by natural compounds and environmental chemicals have been rarely addressed. In our in vitro study, we investigated putative antiprogestin activities of the plant compounds apigenin (API) and trans-ferulic acid (t-FA) as well as the UV absorbers octyl methoxycinnamate (OMC) and 4-methylbenzylidene camphor (4-MBC). They were compared with the selective progesterone receptor modulators (SPRMs) mifepristone (RU486) and ulipristal acetate (UPA) as well as the full PR-antagonist ZK137316. Effects of test compounds in combination with progesterone on the progesterone-sensitive target gene estrogen sulfotransferase (SULT1E1) were characterized by sigmoidal concentration-response curves obtained by RT-qPCR. The agonistic effect of progesterone on SULT1E1 mRNA levels was concentration-dependently antagonized by RU486, UPA and ZK137316 as well as, with lower potency, apigenin. t-FA, OMC and 4-MBC had no effect on SULT1E1 mRNA levels. We demonstrated that apigenin, although at higher concentrations, exerts a similar effect as the well-characterized SPRMs RU486 and UPA or the progesterone antagonist ZK137316 in this model. Our endometrium-specific Ishikawa cell assay is a useful complement to artificial transactivation assays for the identification of environmental substances with antiprogestin activities.


Subject(s)
Endometrium , Hormone Antagonists/pharmacology , Phytochemicals/pharmacology , Receptors, Progesterone/antagonists & inhibitors , Sulfotransferases/drug effects , Sunscreening Agents/pharmacology , Apigenin/pharmacology , Camphor/analogs & derivatives , Camphor/pharmacology , Cell Line, Tumor , Coumaric Acids/pharmacology , Endometrium/drug effects , Endometrium/metabolism , Female , Humans , Mifepristone/pharmacology , Norpregnadienes/pharmacology
3.
Gynecol Endocrinol ; 24(6): 306-11, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18584409

ABSTRACT

Nitric oxide (NO) is considered to be involved in the modulation of uterine contractility. In the present pilot study, the direct detection of intracellular NO in pregnant human myometrial tissues has been investigated by using the fluorescent indicator 4,5-diaminofluorescein-2 diacetate (DAF-2DA). Pregnant myometrial tissue samples were obtained during Cesarean sections between week 34 and 40 of gestation before the onset of labor. Living explants were loaded with 10 microM DAF-2DA, stimulated with 1 mM arginine, subsequently fixed with glutaraldehyde and examined by fluorescence microscopy. The presence of NO synthases (NOS) was studied by immunohistochemistry. After application of DAF-2DA, DAF fluorescence was located primarily in blood vessels and to a minor extent in myometrial cells. By immunohistochemistry, strong endothelial NOS (eNOS) staining was found in vessel walls. In myometrial cells weak staining of eNOS and inducible NOS was observed. We conclude that the direct NO detection by DAF-2DA provides a new and independent method to identify sites of NO production in myometrium and other heterogeneous tissues.


Subject(s)
Fluorescein/chemistry , Fluorescent Dyes/chemistry , Myometrium/chemistry , Nitric Oxide/analysis , Female , Humans , Immunohistochemistry , Indicators and Reagents/chemistry , Microscopy, Fluorescence/methods , Myometrium/enzymology , Myometrium/metabolism , Nitric Oxide/metabolism , Nitric Oxide Synthase Type I/analysis , Nitric Oxide Synthase Type I/metabolism , Nitric Oxide Synthase Type II/analysis , Nitric Oxide Synthase Type II/metabolism , Nitric Oxide Synthase Type III/analysis , Nitric Oxide Synthase Type III/metabolism , Pilot Projects , Pregnancy
4.
Anal Bioanal Chem ; 383(5): 768-75, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16189679

ABSTRACT

In this article real-time quantitative RT-PCR strategies for investigation of mRNA distribution in stress-related corticotropin-releasing hormone (CRH), CRH-binding protein (CRH-BP), and CRH receptors (CRH-R1, CRH-R2) in human gestational tissues are described. The effect of sample and RNA preparation, reverse transcription, and the quantitation strategy were investigated. Both thawing of the sample before homogenization and the RT reaction were identified as critical steps. In contrast, the time-lag from the biopsy until snap-freezing and the homogenization procedure had little effect. The "housekeeping" gene cyclophilin was found to be differently expressed in gestational tissues, compromising its use as internal reference. For relative quantitation of mRNA levels by TaqMan PCR the standard curve method and the comparative C (T) method (DeltaDeltaC (T) or DeltaC (T)' method) were compared. Both calculation strategies delivered similar relative mRNA amounts in identifying the placenta as the main source of CRH and CRH-BP mRNA compared with myometrium and decidua. Consistent results were also obtained for CRH-R1 and CRH-R2 by both methods of calculation. We conclude that the simpler comparative C (T) method is adequate for assessing the mRNA levels of CRH, CRH-BP, and CRH receptors in human gestational tissues.


Subject(s)
Carrier Proteins/analysis , Corticotropin-Releasing Hormone/analysis , Placenta/metabolism , Pregnancy/metabolism , Receptors, Corticotropin-Releasing Hormone/analysis , Reverse Transcriptase Polymerase Chain Reaction/methods , Uterus/metabolism , Algorithms , Female , Gene Expression Profiling/methods , Humans , Reproducibility of Results , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...